Development of a Rapid Reverse Blot Hybridization Assay for Detection of Clinically Relevant Antibiotic Resistance Genes in Blood Cultures Testing Positive for Gram-Negative Bacteria by Hye-young Wang et al.
METHODS
published: 09 February 2017
doi: 10.3389/fmicb.2017.00185
Frontiers in Microbiology | www.frontiersin.org 1 February 2017 | Volume 8 | Article 185
Edited by:
John W. A. Rossen,
University Medical Center Groningen,
Netherlands
Reviewed by:
Ferry Hagen,
Canisius-Wilhelmina Hospital,
Netherlands
Eefje Schrauwen,
Amphia hospital, Netherlands
*Correspondence:
Young Uh
u931018@yonsei.ac.kr
Hyeyoung Lee
hyelee@yonsei.ac.kr
†
These authors have contributed
equally to this work.
Specialty section:
This article was submitted to
Infectious Diseases,
a section of the journal
Frontiers in Microbiology
Received: 08 November 2016
Accepted: 25 January 2017
Published: 09 February 2017
Citation:
Wang H-y, Yoo G, Kim J, Uh Y,
Song W, Kim JB and Lee H (2017)
Development of a Rapid Reverse Blot
Hybridization Assay for Detection of
Clinically Relevant Antibiotic
Resistance Genes in Blood Cultures
Testing Positive for Gram-Negative
Bacteria. Front. Microbiol. 8:185.
doi: 10.3389/fmicb.2017.00185
Development of a Rapid Reverse Blot
Hybridization Assay for Detection of
Clinically Relevant Antibiotic
Resistance Genes in Blood Cultures
Testing Positive for Gram-Negative
Bacteria
Hye-young Wang 1†, Gilsung Yoo 2†, Juwon Kim 2, Young Uh 2*, Wonkeun Song 3,
Jong Bae Kim 4 and Hyeyoung Lee 4*
1Optipharm M&D, Inc., Wonju Eco Environmental Technology Center, Wonju, Gangwon, South Korea, 2Department of
Laboratory Medicine, Yonsei University Wonju College of Medicine, Wonju, South Korea, 3Department of Laboratory
Medicine, Hallym University College of Medicine, Seoul, South Korea, 4Department of Biomedical Laboratory Science,
College of Health Sciences, Yonsei University, Wonju, South Korea
Rapid and accurate identification of the causative pathogens of bloodstream infections
is crucial for the prompt initiation of appropriate antimicrobial therapy to decrease
the related morbidity and mortality rates. The aim of this study was to evaluate the
performance of a newly developed PCR-reverse blot hybridization assay (REBA) for
the rapid detection of Gram-negative bacteria (GNB) and their extended-spectrum
β-lactamase (ESBL), AmpC β-lactamase, and carbapenemase resistance genes
directly from the blood culture bottles. The REBA-EAC (ESBL, AmpC β-lactamase,
carbapenemase) assay was performed on 327 isolates that were confirmed to have
an ESBL producer phenotype, 200 positive blood culture (PBCs) specimens, and
200 negative blood culture specimens. The concordance rate between the results of
REBA-EAC assay and ESBL phenotypic test was 94.2%. The sensitivity, specificity,
positive predictive value, and negative predictive value of the REBA-EAC assay for GNB
identification in blood culture specimens were 100% (95% CI 0.938–1.000, P < 0.001),
100% (95% CI 0.986–1.000, P < 0.001), 100% (95% CI 0.938–1.000, P < 0.001),
and 100% (95% CI 0.986–1.000, P < 0.001), respectively. All 17 EAC-producing GNB
isolates from the 73 PBCs were detected by the REBA-EAC assay. The REBA-EAC
assay allowed easy differentiation between EAC and non-EAC genes in all isolates.
Moreover, the REBA-EAC assay was a rapid and reliable method for identifying GNB
and their β-lactamase resistance genes in PBCs. Thus, this assay may provide essential
information for accelerating therapeutic decisions to achieve earlier appropriate antibiotic
treatment during the acute phase of bloodstream infection.
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INTRODUCTION
Antibiotic resistance among pathogenic organisms has become a
major healthcare problem worldwide, with serious consequences
for the treatment of infectious diseases (Gottlieb and Nimmo,
2011). Early targeted antibiotic treatment is an important
prognostic factor, especially for seriously ill patients (Cosgrove,
2006). Among the GNB, the Enterobacteriaceae family
includes the most widespread pathogens causing infectious
diseases; its members are among the most common causes of
nosocomial infection. Beta-lactamase production is the major
resistance mechanism of the Enterobacteriaceae. Specifically,
extended-spectrum β-lactamases (ESBLs), plasmid-mediated
cephalosporinases (pAmpCs), and carbapenemases pose major
therapeutic challenges in the treatment of hospitalized and
community-based patients. Rapid and accurate identification of
β-lactamase-producing Enterobacteriaceae is crucial for reducing
clinical failure due to the use of inappropriate antimicrobial
therapy and for preventing nosocomial outbreaks.
The CLSI has released recommendations for the detection
of ESBLs in clinical isolates of Klebsiella pneumoniae, Klebsiella
oxytoca, Escherichia coli, and Proteus mirabilis using clavulanic
acid (CLSI, 2015). However, no guidelines have yet been issued
for the detection of AmpCs. Moreover, the occurrence of bacteria
that co-produce ESBLs and AmpCs has become a serious
issue in the context of Enterobacteriaceae β-lactam resistance.
Furthermore, overproduction of AmpCs in association with
a porin defect can lead to carbapenem resistance (Jacoby,
2009). Although the modified Hodge test for carbapenemases
has been found to be a useful tool for the detection of
carbapenemase-producing Enterobacteriaceae, this test lacks
sensitivity for NDM carbapenemases. Moreover, false positive
results can occur in isolates that produce ESBL or AmpC
enzymes coupled with porin loss.
Currently, molecular diagnostic methods such as real-time
PCR (qPCR) (Beuving et al., 2011), mass spectrometry (Chong
et al., 2015), microarray (Card et al., 2013), and loop-mediated
isothermal amplification-based systems (García-Fernández et al.,
2015) are available for bacterial identification and discrimination
of antimicrobial susceptibility. However, DNA-based ESBL
identification is technically challenging because new ESBLs are
derived from pre-existing class A β-lactamases by several single
amino acid substitutions (Rubtsova et al., 2010).
In this study, we evaluated a PCR-based reverse blot
hybridization assay (REBA) that was recently developed for
the rapid detection of GNB and their ESBL, AmpC, and
carbapenemase (EAC) resistance genes. Specifically, the REBA-
EAC assay was designed to detect ESBLs (CTX-M-, TEM-, and
SHV-type), AmpCs (ACT, CMY-2-like, DHA, ACC-1, CMY-1-
like/MOX, and FOX), and carbapenemases (IMP, VIM, NDM,
KPC, OXA-48-like, and SPM).
MATERIALS AND METHODS
Archived Isolates
To determine the specificity of the REBA-EAC assay, we tested
archived frozen stocks of 29 EAC-producing Enterobacteriaceae
strains (Song et al., 2015) and 128 non-EAC-producing
clinical isolates belonging to 35 different genera [Citrobacter
(1), Enterobacter (2), Escherichia (9), Klebsiella (3), Leclercia
(1), Proteus (3), Salmonella (5), Serratia (1), Shigella (4),
Bordetella (1), Haemophilus (1), Acinetobacter (1), Pseudomonas
(2), Enterococcus (17), Micrococcus (1), Staphylococcus (12),
Streptococcus (5), Corynebacterium (1), Mycobacterium (23),
Absidia (1), Aspergillus (7), Aureobasidium (1), Beauveria (1),
Bipolaris (1), Candida (8), Cryptococcus (1), Curvularia (1),
Epidermophyton (1), Fusarium (1), Kodamaea (1), Malassezia
(1), Microsporum (3), Penicillium (2), Saccharomyces (1),
and Trichophyton (4)] from various specimen types. The
29 EAC-producing Enterobacteriaceae isolates included 11
ESBL-producing, 9 AmpC-producing, and 9 carbapenemase-
producing strains (Table 1).
Clinical Isolates
To assess the diagnostic performance of the REBA-EAC assay,
327 ESBL phenotype clinical isolates obtained from 2010 to
2014 at Wonju Severance Christian Hospital (WSCH) were used.
Isolates were identified by conventional identification method
including phenotypic characteristics such as colony morphology,
Gram staining result, and commercial identification kit results.
MicroScan (Beckman Coulter, Brea, CA, USA) overnight Pos
BP Combo 28, MICroSTREP Plus, overnight Neg Combo 53
and Neg Combo 54 panels were used for the identification
of GPB, streptococci and GNB. For the identification of
Candida spp., VITEK 2 (bioMérieux, Durham, NC, USA) yeast
identification card was used. The ESBL phenotype of each isolate
was confirmed by the microbroth dilution method, which is
the test recommended by the CLSI. AmpC β-lactamase and
carbapenemase production was confirmed using qPCR and by
sequencing analyses with EAC primers (Table 2). This study
was approved by the Institutional Ethics Committee at Yonsei
University Wonju College of Medicine (approval no. CR312055-
002) and samples were de-identified.
DNA Preparation
To prepare DNA templates for the REBA-EAC assay, one
colony from each frozen stock and one colony from each
clinical isolate was suspended in 100 µL of DNA extraction
solution (Optipharm, Osong, Republic of Korea). The bacterial
suspension was boiled for 10 min. After centrifugation at 13,000
× g for 10 min, the supernatant was used as a source of DNA
template.
REBA-EAC Primers and Probes
The 26 specific primers and probes were used for the detection
of GNB (10 probes) and their antibiotic resistance genes (16
EAC gene probes) and an example of the result is shown
in Figure 1. The sequences of the primers and probes were
compared by nucleotide-nucleotide NCBI BLAST (BLASTn)
searches to determine their sequence homologies. Primers and
probes were selected by multiple alignments using the MultAlign
program (http://multalin.toulouse.inra.fr/multalin/). All publicly
available nucleotide sequences of the TEM and SHV alleles
related to the ESBL-production phenotype (http://www.lahey.
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TABLE 1 | Characteristics of the 29 EAC-producing Enterobacteriaceae
isolates with ESBL, AmpC β-lactamase, and carbapenemase resistance
genes.
Organism type (no. of isolates) Stock no. Resistance gene
ESBL STRAINS (11)
Escherichia coli DML1101 CTX-M-1
E. coli DML1786 CTX-M-1
E. coli DML1100 CTX-M-9
E. coli DML1780 SHV-2a
E. coli DML1783 SHV-2a
E. coli DML1784 SHV-151
E. coli DML1785 SHV-28
Klebsiella pneumoniae DML1098 CTX-M-1
K. pneumoniae DML1095 SHV-12
K. pneumoniae DML1098 SHV-28
Shigella spp. DML1096 TEM-52
AmpC β-LACTAMASES (9)
E. coli DLMH 71 CMY-2-like
E. coli DML1784 CMY-11
E. coli DLMH 173 CMY-1-like/MOX
E. coli DLM 256 ACC-1
K. pneumoniae DLMH 70 DHA-1
K. pneumoniae DLMH 585 DHA-1
K. pneumoniae DLMH 492 CMY-1-like/MOX
Enterobacter cloacae DML1099 ACT
E. cloacae DML1781 ACT
CARBAPENEMASES (9)
K. pneumoniae DLMH 411 OXA-232
K. pneumoniae DLMH 107 OXA-48-like
K. pneumoniae DLMH 108 OXA-181
K. pneumoniae DLMH 492 NDM
E. coli DLMH 410 OXA-232
E. coli DLMH 744 KPC
E. cloacae DML 1781 VIM
E. cloacae DLMH 568 VIM
Pseudomonas aeruginosa DLMH 155 IMP
DML, Diagnostic Microbiology Laboratory of Yonsei University (Wonju, Republic of Korea);
DLMH, Department of Laboratory Medicine of Hallym University College of Medicine
(Seoul, Republic of Korea).
org/studies/) were retrieved from GenBank. Previous reports
have concluded that 95% of all TEM-variants with an established
ESBL phenotype have one or more amino acid substitutions at
positions 39, 104, 164, 238, and/or 240; moreover, 77% of all ESBL
SHV-variants have substitutions at positions 179, 238, and/or 240
(Cohen Stuart et al., 2010; Rubtsova et al., 2010). Based on these
findings, 7 oligonucleotide probes (Figure 1) were designed to
identify TEM-variants (one TEM-all probe and 6 probes for ESBL
variants). Specifically, the probes were designed to detect the
following ESBL-associated amino acid substitutions: Gln39Lys,
Glu104Lys, Arg164Ser/His, Gly238Ser, and/or Glu240Lys. To
identify SHV-variants, 6 probes (Figure 1) were designed (one
SHV-all probe and 5 probes for ESBL variants). Specifically, the
probes were designed to detect the following ESBL-associated
TABLE 2 | Primers and probes for REBA-EAC and qPCR.
Target and primer/
probe name
Nucleotide sequence (5′-3′) Product size
ESBLs
CTX-M-1-210-F GATGTGCAGCACCAGTAAAGTGATG 203 bp
CTX-M-1-413-R ATCGCCACGTTATCGCTGTACTG
CTX-M-1/2-258-P AAGTGAAAGCGAACCGAATCTGTTA
CTX-M-9-210-F TGTGCAGTACCAGTAAAGTTATGGCG 170 bp
CTX-M-9-380-R GCGCTAAGCTCAGCCAGTGACA
CTX-M-9-261-P GAAACGCAAAAGCAGCTGCTT
TEM-520-F TGCTCACCCAGAAACGCTGGT 705 bp
TEM-1225-R ACGATACGGGAGGGCTTACCAT
Gln39Lys-P AAAGATGCTGAAGATAAGTTGGGTG
Glu104Lys-P CCAACTATCAAGGCGGGTTACA
Gly164His-P TTCCCAATGATCAAGGCGAGTTA
Gly238Ser-P GAGATCCATGCTCACCGGCTC
Glu240Lys-P GAGATCCATGCTCACCGGCTC
TEM-127-Fa GGTTACATCGAGCTGGATCTCAACA 360bp
TEM-488-Ra CAACGATCAAGGCGGGTTACAT
SHV-243-F TATTATCTCCCTGTTAGCCACCCT 717 bp
SHV-960-R CCAAGCAGGGCGACAATCC
Leu35Gln-P GGCTTTCGCTTTGTTTAATTTGCTC
Asp179Ala-P GCCCGCACCACCACTA
SHV-147-Fb GCAAATTAAACAAAGCGAAAGCCA 133bp
SHV-280-Rb GCACTACTTTAAAGGTGCTCATCATGG
AmpC β-LACTAMASES
ACT-MIR-416-F TACAGGTRCCGGATGAGGTCACG 205 bp
ACT-MIR-620-R CTATGGTCCAGCTTGAGCGGCTTAA
ACT-MIR-464-P ATCAAAACTGGCAGCCGCAG
CMY-2-like-261-F AAGACGTTTAACGGCGTGTTGG 175 bp
CMY-2-like-436-R TAACGTCATCGGGGATCTGCA
CMY2-like-328-P ACGAAATACTGGCCAGAACTGACA
DHA-261-F TTTCACAGGTGTGCTGGGTGC 200 bp
DHA-460-R AGAAATTCAGCAGATCCGCACGG
DHA-299-P AAGAGATGGCGCTGAATGATCC
ACC-1-410-F ACGT AGCGTAACAAGTCGCTGGAG 210 bp
ACC-1-620-R TGGGTGTGAGCTATGAAGATGCGATT
ACC-1-439-P GCTTCGTTACCCAAAATCTCCATATTC
CMY-1-like/MOX-128-F CTGCTCAAGGAGCACMGGATC 243 bp
CMY-1-like/MOX-371-R CGGATCCCTTGAGCCAGGG
CMY-1-like/MOX-172-P AAAGGATGGCAAGGCCCACTA
FOX-182-F ATTTCAACTATGGGGTTGCCAACC 208 bp
FOX-390-R AAGCTCGGCCATRGTCACACCATC
FOX-239-P TGTTCGAGATTGGCTCGGTCAG
CARBAPENEMASES
IMP-263-F TAAAAGGCAGTATYTCCTCWCATTT 232 bp
IMP-495-R CCAAACCACTACGTTATCTKGAG
IMP-307-P GGAATAGAGTGGCTTAATTCTCRATCTAT
VIM-136-F CTTTACCAGATTGCCGATGGTGTT 214 bp
VIM-350-R TCATGAAAGTGCGTGGAGACTGCA
VIM-198-P CTACCCGTCCAATGGTCTCATTGT
KPC-269-F TGGACACACCCATCCGTTACG 211 bp
KPC-480-R ACGGAACGTGGTATCGCCGATAG
(Continued)
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TABLE 2 | Continued
Target and primer/
probe name
Nucleotide sequence (5′-3′) Product size
KPC-329-P AATATCTGACAACAGGCATGACGGT
NDM-327-F AGATCCTCAACTGGATCAAGCAGG 223 bp
NDM-550-R TGCTGGTTCGACCCAGCCATTGGC
NDM-385-P TCACGCGCATCAGGACAAGA
OXA-48-like-131-F TTGTGCTCTGGAATGAGAATAAGCAG 210 bp
OXA-48-like-340-R CGGTGATTAGATTATGATCGCA
OXA-48-186-P GAACCAAGCATTTTTACCCGCA
SPM-50-F CGGATCATGTCGACTTGCCCT 200 bp
SPM-250-R ACTACTTTCTTCGGCTTCATAGTC
SPM-107-P TCGTCACAGACCGCGATTTCT
a,bPrimers for qPCR.
substitutions: Leu35Gln, Asp179, Gly238Ser, and/or Glu240Lys
(Cohen Stuart et al., 2010; Rubtsova et al., 2010).
PCR
PCR was performed in a final reaction volume of 20 µL. Each
reaction contained 2×master mix (10 µL) (GeNet Bio, Daejeon,
Republic of Korea), 5 µL primer mixture, and 5 µL sample DNA.
The first 10 PCR cycles were comprised of denaturation at 95◦C
for 30 s, followed by annealing and extension at 60◦C for 30 s.
These 10 cycles were followed by 40 cycles of denaturation at
95◦C for 30 s and annealing/extension at 54◦C for 30 s. After
the final cycle, samples were maintained at 72◦C for 10 min to
complete the synthesis of all strands. The amplicon was visualized
as a single 230 bp band using a ChemiDoc system (Bio-Rad,
Hercules, CA, USA).
REBA-EAC Assay
To validate the efficiency of the selected probes, target DNA
samples amplified from EAC-producing strains were applied
to REBA membrane strips spotted with the selected probes.
Two genes (FOX and SPM) were synthesized (Bioneer, Daejeon,
Republic of Korea) and amplified with custom PCR primers
(FOX, F-5′-ATGCAACAACGACGTGCGTTCGC-3′ and R-5′-
TGGCAAGCTCGGCCATGGTCAC-3′; SPM, F-5′-CGTTTTG
TTTGTTGCTCGTTGCG-3′ and R-5′-TCAGCTGCTTTTATC
CGGTCTTTC-3′), resulting in amplicons of 395 and 400 bp,
respectively. The resultant products were mutagenized after
subcloning into the pBHA vector. Two plasmids were extracted
from the transformants, and the mutated sequences were
confirmed by sequence analysis (CosmoGenetech, Seoul, South
Korea).
For the REBA-EAC assay, hybridization and washing were
performed according to the manufacturer’s instructions. Each
sample was tested in duplicate and all REBA experiments
were performed twice. In brief, biotinylated PCR products
were denatured at 25◦C for 5 min in denaturation solution.
The resulting single-stranded PCR products were transferred
to hybridization solution and then incubated with REBA-EAC
membrane strips at 55◦Cwith shaking at 90 rpm for 30min in the
provided blotting tray. The strips were then washed twice with
gentle shaking in 1 mL of washing solution for 10 min at 55◦C,
incubated at 25◦C with a 1:2,000 dilution of streptavidin-alkaline
phosphatase (AP) conjugate (Roche Diagnostics, Mannheim,
Germany) in conjugate diluent solution (CDS) for 30 min, and
finally, washed twice with 1 mL CDS at room temperature for
1 min. The colorimetric hybridization signals were visualized by
the addition of a 1:50 dilution of the NBT/BCIP AP-mediated
staining solution (RocheDiagnostics), and incubated until a color
change was detected. Finally, the banding pattern was read and
interpreted.
Real Time PCR (qPCR) Assay
All phenotypic ESBL producers were screened by qPCR (CFX-96
qPCR system; Bio-Rad) to identify their non-ESBL and ESBL-
carrying genes using primers specific for detecting predominant
subtypes of CTX-M, TEM, and SHV. Next, the AmpC- and
carbapenemase-carrying genes were analyzed using qPCR (CFX-
96 qPCR system; Bio-Rad). Specifically, the presence of genes
encoding ACT, CMY-2-like, DHA, ACC-1, CMY-1-like/MOX,
FOX, IMP, VIM, NDM, KPC, OXA-48-like, and SPM was
analyzed (Table 2). qPCR amplification was performed in a total
volume of 20 µL, including 10 µL of 2× Thunderbird SYBR
master mix (Toyobo, Osaka, Japan), 2 µL primer mixture, 5 µL
template DNA, and 3 µL sterile distilled water. Each qPCR assay
included internal control DNA that was used to simulate pure
nucleic acid extraction and high sample quality, thus monitoring
the effect of PCR inhibitors in the reaction. Positive and negative
controls were also included throughout the procedure. Template
controls containing sterile distilled water were also incorporated
in each assay. The thermocycling conditions were as follows:
95◦C for 3 min, followed by 40 cycles of 95◦C for 3 s and 60◦C
for 30 s. Each sample was tested in duplicate and all PCR assays
were performed twice. The relative bacterial load was quantified
by determining the cycle threshold (CT), i.e., the number of
PCR cycles required for the fluorescence to exceed a value
significantly higher than the background fluorescence. A positive
result was interpreted as when the CT value was less than 30 after
fluorescence signal above background was observed.
Sequence Analysis
The PCR amplicons of all clinical isolates in this study were
sequenced using an ABI 3730 automated DNA sequencer
(Applied Biosystems, Foster City, CA, USA) and an ABI Prism
BigDye Terminator (Applied Biosystems) system. The obtained
sequences were compared with sequences in the NCBI GenBank
database for species assignment.
Blood Culture Samples
To evaluate the diagnostic performance of the REBA-EAC assay
on blood culture samples, 200 positive blood culture (PBC),
and 200 negative blood culture (NBC) samples were collected
at WSCH from April 2015 to June 2015. Blood samples were
drawn from the patient at the bedside. Three or two pairs of
culture bottles were inoculated with the blood samples and then
incubated in a BacT/Alert 3D (bioMérieux, Durham, NC, USA)
or BACTEC FX (Becton Dickinson Diagnostic Systems, Spark,
MD, USA) blood culture system for 5 days. If no bacterial growth
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FIGURE 1 | Results of the REBA-EAC assay. (A) Results of the REBA-EAC assay for the detection of TEM/SHV-ESBLs: Lane 1, E. coli; 2, TEM-1; 3, TEM-73; 4,
TEM-ESBL (Glu104Lys); 5, TEM-ESBL (Gly238Ser); 6-7, TEM-52 and TEM-66 (Glu104Lys and Gly238Ser mixed); 8, K. pneumoniae; 9, SHV-1; 10, SHV-ESBL
(Asp179Ala); 11-12, SHV-12 and SHV-2a (Gly238Ser). (B) Specificity of the REBA-EAC assay as tested with DNA from 16 EAC-producing and 6 reference bacterial
species: Lane 1, CTX-M-1-2; 2, CTX-M-9; 3, TEM; 4, SHV; 5, ACT; 6, CMY-2-like; 7, DHA; 8, ACC-1; 9, CMY-1-like/MOX; 10, FOX; 11, IMP; 12, VIM; 13, NDM; 14,
KPC; 15, OXA-48-like; 16, SPM; 17, E. coli; 18, Enterobacter aerogenes; 19, K. pneumoniae; 20, Serratia marcescens; 21, P. aeruginosa; 22, A. baumannii; N,
negative control.
was detected within 5 days, the blood culture was considered
to be negative. When bacterial growth was noted, the culture
sample was inoculated onto blood and MacConkey agar plates
(Becton Dickinson) and cultured overnight at 37◦C in a 5% CO2
incubator.
For the preparation of DNA templates from the PBC andNBC
samples, 0.5 mL of blood suspension was withdrawn directly
from the culture bottle. Next, 1 mL of phosphate-buffered saline
(pH 8.0) was added and the sample was spun by centrifugation at
13,000 × g for 1 min. The supernatant was then removed, after
which the pellet was resuspended in 1mL of erythrocyte lysis
buffer (Sigma, St. Louis, MO, USA) and spun by centrifugation
at 13,000 × g for 1min. This wash step was repeated twice.
The pellet was then resuspended in DNA extraction solution, as
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described above for the clinical isolates. To confirm the positive
results from the REBA-EAC assay, qPCR and sequence analyses
were performed using the same DNA samples.
Statistical Analysis
All statistical analyses were performed using Prism 5 software
(GraphPad, La Jolla, CA, USA) and SPSS statistics software
version 21.0 (IBM, Armonk, NY, USA). The sensitivity,
specificity, negative predictive value, and positive predictive value
of the qPCR and REBA-EAC assays were analyzed by calculating
the kappa coefficient of the predictive ability, its corresponding P
value, and the 95% confidence interval (CI).
RESULTS
Analytical Sensitivity and Specificity of the
REBA-EAC Assay
Twenty-nine EAC-producing strains were identified using the
designated target probes in the REBA-EAC assay, whereas 128
non-EAC-producing clinical isolates yielded negative results by
the REBA-EAC assay (data not shown). No cross-genus or cross-
species reactivity was observed.
The REBA-EAC assay was able to detect single nucleotide
polymorphisms found in themost prevalent TEM- and SHV-type
ESBLs, including Gln39Lys, Glu104Lys, Arg164Ser, Gly238Ser,
and/or Glu240Lys in the TEMs, and Asp179Ala/Asn/Gly,
Gly238Ser/Ala, and/or Glu240Lys in the SHVs. TEM-52, TEM-
66 (Glu104Lys and Gly238Ser mixed), and SHV-12 (Gly238Ser),
which were identified as TEM/SHV-ESBLs by the REBA-
EAC assay, were also confirmed ESBL-associated amino acid
substitutions by sequence analyses. The target DNA samples
hybridized strongly with the probes derived from their targets
and showed no cross-reactivity (Figure 1). The analytical
sensitivities of the 16 target probes (4 ESBL, 6 AmpC, and
6 carbapenemase probes) were determined using a standard
curve of 10-fold dilutions (10 ng, 1 ng, 100 pg, 10 pg, 1 pg, 100 fg,
and 10 fg) of DNA extracted from EAC-producing strains. The
detection limit of the REBA-EAC assay for each probe ranged
from 100 fg to 10 fg DNA per reaction (Figure 2).
Diagnostic Performance of the REBA-EAC
Assay for Clinical Isolates
Based on the genus-specific or species-specific REBA-EAC assay
probes, the overall concordance rate of the assay for species
identification of the 327 Enterobacteriaceae isolates between
the conventional identification test and the REBA-EAC assay
was 100%. Of the 327 ESBL-phenotypically confirmed isolates,
308 isolates (94.2%) were positive by the REBA-EAC assay
for ESBL genes, 16 K. pneumoniae isolates had only AmpC
plasmid-mediated DHA genes, and three E. coli isolates did
not have any EAC genes by the REBA-EAC assay (Table 3).
Among the 324 isolates with at least one EAC gene, exclusive
ESBL-producing isolates accounted for up to 70.0% of all EAC-
producers (one-type ESBL producer, 154 isolates; two-type ESBL
co-producer, 73 isolates), followed by 23.1% for ESBL and AmpC
β-lactamase; 4.9% for AmpC β-lactamase; 1.5% for ESBL and
carbapenemase; and 0.3% for ESBL, AmpC, and carbapenemase
(Table 3). Overall, 80.2% (247/308) of ESBL-producing isolates
were the CTX-M type, with CTX-M-9 group (57.5%) being the
most prevalent ESBL gene. For the TEM and SHV genes, the
REBA-EAC assay was able to differentiate between non-ESBL
TEM/SHV, and their ESBL derivatives for all isolates. Among the
FIGURE 2 | Detection limits of the REBA-EAC assay for the 16 EAC gene probes. Limits were determined using 10-fold serial dilutions of DNA samples from
EAC-producing strains. A, CTX-M-1; B, CTX-M-9; C, TEM; D, SHV; E, ACT; F, CMY-2-like; G, DHA; H, ACC-1; I, CMY-1-like/MOX; J, FOX; K, IMP; L, VIM; M, NDM; N,
KPC; O, OXA-48-like; and P, SPM. Lane 1, 10 ng; Lane 2, 1 ng; Lane 3, 100 pg; Lane 4, 10 pg; Lane 5, 1 pg; Lane 6, 100 fg; Lane 7, 10 fg, Lane 8, negative control.
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TABLE 3 | REBA-EAC assay results for the detection of ESBLs, AmpC
β-lactamases, and carbapenemases in the 327 ESBL-phenotypically
confirmed isolates.
ESBL-phenotypically
confirmed isolate
(no. of isolates)
REBA-EAC assay
GN-ID (no. of
isolates)
β-lactamase content
(no. of isolates)
Escherichia coli (196) E. coli (196) CTX-M only (109)
CTX-M + TEM-type ESBL (68)
TEM-type ESBL (5)
CTX-M + CMY2 (4)
CTX-M + DHA (2)
CTX-M + NDM (2)
CTX-M + ACT (1)
CTX-M + KPC (1)
CTX-M + VIM (1)
ND (3)
Klebsiella pneumoniae
(120)
K. pneumoniae (120) CTX-M + DHA (58)
TEM-type ESBL (11)
CTX-M only (10)
SHV-type ESBL (9)
CTX-M + CMY2 (7)
CTX-M + SHV-type ESBL (5)
CTX-M + DHA + CMY2 (2)
CTX-M + IMP (1)
CTX-M + DHA + NDM (1)
DHA only (16)
Proteus mirabilis (4) Gram negative (4) CTX-M (4)
Klebsiella oxytoca (3) K. oxytoca (2) SHV-type ESBL (2)
K. oxytoca (1) CTX-M (1)
Enterobacter spp. (3) Enterobacter spp. (2) CTX-M (2)
Enterobacter spp. (1) CTX-M + ACT (1)
Providencia stuartii (1) Gram negative (1) CTX-M (1)
ND, not detected.
144 pan-TEM-positive isolates tested by qPCR, 104 (72.2%) were
positive for G104L (TEM-3, -22, -52, -66), G238S, and/or G240L
(TEM-22, -46, -52). Moreover, remaining 40 (27.8%) isolates,
which were negative for G104L, G238S, and/or G240L, were
considered to be non-ESBL producers by both the REBA-EAC
assay and sequence analysis. The SHV-ESBL specific amino acid
substitution, G238S, was detected in 31 (26.1%) of the 119 SHV-
producing Klebsiella spp., and was confirmed in the SHV-2a, -5,
and -12 genes by sequence analysis (Table 4).
Diagnostic Performance of the REBA-EAC
Assay for Blood Culture Samples
Typical results of the REBA-EAC assay using blood culture
samples are shown in Figure 3. Among the 200 PBC samples,
120 (60%), 73 (36.5%), and 7 (3.5%) samples contained GPB,
GNB, and Candida species by the conventional identification
test, respectively. None of the GPB or Candida species were
detected by the REBA-EAC assay (Table 5). Based on the
genus-specific or species-specific REBA-EAC assay probes, the
sensitivity, specificity, positive predictive value, and negative
predictive value of the REBA-EAC assay for GNB identification
in blood culture specimens were 100% (95% CI 0.938–1.000,
P < 0.001), 100% (95% CI 0.986–1.000, P < 0.001), 100%
(95% CI 0.938–1.000, P < 0.001), and 100% (95% CI 0.986–
1.000, P < 0.001), respectively. Among the 57 Enterobacteriaceae
isolates, only 12 (12/57; 21.1%) isolates were phenotypically
confirmed as ESBL producers, whereas 16 (16/57; 28.1%)
isolates were confirmed as carrying EAC genes by both the
REBA-EAC assay and sequence analysis (Table 6). Eleven of
the twelve (91.7%) phenotypically ESBL-positive isolates also
showed positive results by the REBA-EAC assay, with CTX-
M type genes (8 CTX-M-1 and 3 CTX-M-9) being the most
prevalent ESBL genes. One Pseudomonas aeruginosa and five
Enterobacteriaceae isolates (3 Enterobacter cloacae, 1 Citrobacter
freundii, and 1 Providencia stuartii) were positive for an IMP and
AmpC genes (ACT, CMY, or DHA), respectively, by the REBA-
EAC assay. This finding was confirmed by qPCR and Sanger
sequencing.
DISCUSSION
Presently, antimicrobials are usually selected empirically for the
initial treatment of bacteremia when a bloodstream infection is
strongly suspected (Park et al., 2014). Furthermore, since the
antimicrobial susceptibility results usually cannot be provided
in <48–72 h, clinicians continue to rely on Gram stain results
for selection of an appropriate antibiotic treatment for patients
with PBCs (Uehara et al., 2009). Rapid and accurate EAC
detection is crucial for effective infection control measures
and for the selection of appropriate antimicrobial therapy,
because the emergence of EAC-producing strains is a vital
factor in the treatment of infections associated with sepsis.
Like other mechanisms of antibiotic resistance, the genes for
EACs are most often encoded on plasmids that can be readily
transferred between bacteria (Haenni et al., 2014). The use of
semiautomated systems for the identification and antimicrobial
susceptibility testing of GNB is now routine practice in many
laboratories. Compared to more recently developed molecular
tests, traditional phenotypic susceptibility results usually take an
additional 1–2 days after a PBC is reported. Since phenotypic
detection of ESBLs, AmpCs, and carbapenemases is time-
consuming and the results may be difficult to interpret, a faster
and more accurate detection method is highly desirable for
routine use in clinical laboratories (Cohen Stuart et al., 2010).
In general, commercially available molecular based tests have
been developed for one of ESBL (CTX-M types, TEM, and
SHV), AmpC β-lactamase (CMY-2-like, DHA, FOX, ACC-1,
ACT/MIR, and CMY-1-like/MOX), and carbapenemase (VIM,
IMP, NDM, KPC, andOXA-48-type) genes (Diekema and Pfaller,
2013). In comparison, REBA-EAC assay can provide information
about GNB identification and broad range of clinically relevant
antibiotic resistance genes in GNB.
Although the prevalence of carbapenemase-producing
Enterobacteriaceae strains is still very low (<1%) in Korea,
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TABLE 4 | Comparison of the performances of the REBA-EAC assay versus sequence analysis for detecting β-lactamase genes in the 327
ESBL-phenotypically confirmed isolates.
Class of β-lactamase
(no. of isolates)
Type of β-lactamase gene Microorganism No. of isolates
REBA-EAC assay Sequence analysis
ESBL (382) CTX-M-1/2 CTX-M-1 E. coli 97
CTX-M-1/2 CTX-M-1 K. pneumoniae 3
CTX-M-1/2 CTX-M-1 K. oxytoca 1
CTX-M-1/2 CTX-M-1 E. aerogenes 1
CTX-M-9 CTX-M-9 E. coli 86
CTX-M-9 CTX-M-9 K. pneumoniae 49
CTX-M-9 CTX-M-9 P. mirabilis 4
CTX-M-9 CTX-M-9 E. cloacae 2
CTX-M-9 CTX-M-9 P. mirabilis 4
CTX-M-1/2 + CTX-M-9 CTX-M-1 + CTX-M-9 E. coli 2
CTX-M-1/2 + CTX-M-9 CTX-M-1 + CTX-M-9 K. pneumoniae 1
TEM TEM-3 K. pneumoniae 3
TEM TEM-22 E. coli 21
TEM TEM-22 K. pneumoniae 5
TEM TEM-46 E. coli 9
TEM TEM-46 K. pneumoniae 5
TEM TEM-52 E. coli 25
TEM TEM-52 K. pneumoniae 10
TEM TEM-66 E. coli 21
TEM TEM-66 K. pneumoniae 5
SHV SHV-2a K. pneumoniae 14
SHV SHV-5 K. pneumoniae 5
SHV SHV-12 K. pneumoniae 10
SHV SHV-12 K. oxytoca 2
AmpC β-lactamase (92) DHA DHA-1 K. pneumoniae 61
DHA DHA-23 K. pneumoniae 8
DHA DHA-15 K. pneumoniae 5
DHA DHA-3 K. pneumoniae 1
DHA DHA-1 E. coli 2
CMY-2-like CMY-2 K. pneumoniae 7
CMY-2-like CMY-2 E. coli 4
DHA+CMY-2-like DHA+CMY-2 K. pneumoniae 2
ACT ACT-1 E. coli 1
ACT ACT-1 E. aerogenes 1
Carbapenemase (6) NDM NDM-1 E. coli 2
NDM NDM-1 K. pneumoniae 1
KPC KPC-18 E. coli 1
VIM VIM-2 E. coli 1
IMP IMP-1 K. pneumoniae 1
various types of carbapenemases have been identified (Bae
et al., 2015). In this study, ESBL and AmpC β-lactamase
co-production was seen in 23.1%; ESBL and carbapenemase
co-production in 1.5%; and ESBL, AmpC β-lactamase, and
carbapenemase co-production in 0.3% of the phenotypically
confirmed ESBL-producing Enterobacteriaceae isolates. Several
studies have demonstrated that AmpC β-lactamase with ESBLs
causes treatment failure of cefepime and that inadequate
antimicrobial therapy is an independent risk factor for
mortality or microbiological failure in severely ill patients
with life-threatening infections (Fraser et al., 2006; Park et al.,
2010). Therefore, rapid and accurate identification of drug
resistance genes directly from PBCs is critical for the selection of
appropriate antibiotics in the treatment of bacterial infections.
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FIGURE 3 | Representative results for the REBA-EAC assay performed with clinical isolates and positive blood culture samples. Lanes 1–7, 11–17, and
20–23, EAC-producing strains; lanes 8–10, 18, and 19, non-EAC-producing strains; N, negative control.
TABLE 5 | Comparison of species identification results obtained using the
conventional method versus the REBA-EAC assay on 400 blood culture
samples.
Conventional method (no.) REBA-EAC assay no. (%)
Positive Negative
Positive blood culture (200) 73 (36.5) 127 (63.5)
Gram positive (120) 0 (0) 120 (100)
Gram negative (73) 73 (100) 0 (0)
Candida spp. (7) 0 (0) 7 (100)
Negative blood culture (200) 0 (0) 200 (100)
Total (400) 73 (18.3) 327 (81.7)
In this study, we confirmed that the REBA-EAC assay is a
highly sensitive and specific probe-based method that provides
rapid results and can detect multiple species and drug-resistant
genes simultaneously (Ajbani et al., 2011). The REBA-EAC
assay also showed complete agreement with the conventional
identification test and sequence analysis for the detection of ESBL
(CTX-M groups, TEM-ESBL derivatives, SHV-ESBL derivatives)
and non-ESBL (TEM and SHV) genes. For qPCR, TEM/SHV
show positive results for both ESBL and non-ESBL, which makes
it difficult to differentiate between them. However, as REBA-EAC
assay detects one or more amino acid substitutions in targeted
region, it can discriminate between ESBL TEM/SHV derivatives
and non-ESBL TEM/SHV types. In general, our results are
similar to previous assessments of REBA assay (sensitivity of
95–99% and specificity of 100%) (Kim et al., 2016; Wang et al.,
2016) and other methods such as microarray-based check-points
assay (sensitivity of 94–95% and specificity of 83–100%) (Cohen
Stuart et al., 2010; Card et al., 2013) and MALDI-TOF MS-
based assay (sensitivity of 97–99% and specificity of 94–99%)
(Bork et al., 2015; Chong et al., 2015). Moreover, the performance
of the REBA-EAC assay was better than the E-test (sensitivity
of 71% and specificity of 73%) (Garrec et al., 2011). We also
found that CTX-M type genes (CTX-M-1 and CTX-M-9) were
the most prevalent ESBL-encoding genes. These genes were
detected in almost all of the ESBL-producing Enterobacteriaceae
(in particular, 48.4% of all E. coli isolates), whereas ESBL-type
TEM and SHV genes were present in 20.4 and 6.1% of the
isolates, respectively. These findings are in agreement with other
recent studies showing that CTX-M type genes are the ESBL
genes most frequently expressed by Enterobactericeae (Cantón
et al., 2012). In many Enterobacteriaceae, AmpC expression is
low but inducible in response to β-lactam exposure (Haenni
et al., 2014). Using the REBA-EAC assay, we observed various
types of AmpC β-lactamases (DHA, CMY-2, DHA, and ACT) in
different Enterobacteriaceae species: CMY-2 in E. coli, DHA-1 in
K. pneumoniae or E. coli, and ACT in Enterobacter aerogenes.
In particular, DHA-producing K. pneumoniae isolates were
predominant in Enterobacteriaceae, a finding that is similar to
the results reported in other studies (Park et al., 2010).
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TABLE 6 | Comparison of the results of phenotypic versus molecular assays for the detection of β-lactamases in 73 Gram-negative bacteria isolates from
blood culture samples.
Microorganism No. (%) of isolates Detection of β-lactamases, no. (%) of isolates
Phenotypic assay REBA-EAC assay qPCR Sequence analysis
Positive Negative Positive Negative Positive Negative Positive Negative
E. coli 33 (45.2) 11 (33.3) 22 (66.7) 10a (30.3) 23 (69.7) 20b (60.6) 13 (39.4) 10a (30.3) 23 (69.7)
Klebsiella spp. 14 (19.1) 1c (7.1) 13 (92.9) 1c (7.1) 13 (92.9) 12b (85.7) 2 (14.3) 1c (7.1) 13 (92.9)
Enterobacter spp. 5 (6.8) 0 (0) 5 (100) 3d (60) 2 (40) 3d (60) 2 (40) 3d (60) 2 (40)
Providencia spp. 2 (2.7) 0 (0) 2 (100) 1e (50) 1 (50) 1e (50) 1 (50) 1e (50) 1 (50)
Citrobacter freundii 1 (1.4) 0 (0) 1 (100) 1f (100) 0 (0) 1f (100) 0 (0) 1f (100) 0 (0)
Serratia marcescens 1 (1.4) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
Proteus mirabilis 1 (1.4) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
Campylobacter spp. 1 (1.4) NA NA 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
Acinetobacter spp. 7 (9.6) NA NA 0 (0) 7 (100) 0 (0) 7 (100) 0 (0) 7 (100)
Pseudomonas aeruginosa 6 (8.2) NA NA 1g (16.7) 5 (83.3) 1g (16.7) 5 (83.3) 1g (16.7) 5 (83.3)
Sphingomonas paucimobilis 1 (1.4) NA NA 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
Burkholderia cepacia 1 (1.4) NA NA 0 (0) 1 (100) 0 (0) 1 (100) 0 (0) 1 (100)
a Isolates with CTX-M gene (8 CTX-M-1 and 2 CTX-M-9).
bSome of isolates with non-ESBL type TEM or SHV genes were included in the positive results.
c Isolate with CTX-M gene (CTX-M-9).
d Isolates with ACT gene.
e Isolate with DHA gene.
f Isolate with CMY gene
g Isolate with IMP gene.
NA, not available.
Our study confirmed that REBA-EAC assay can be applied
directly in blood culture samples. As shown in Table 5, the
results of conventional identification test and REBA-EAC
assay were completely concordant in species identification.
Furthermore, REBA-EAC assay detected isolates harboring
AmpC or carbapenema genes (1 Pseudomonas aeruginosa, 3
Enterobacter cloacae, 1 Citrobacter freundii, and 1 Providencia
stuartii).
One potential limitation of our study compared to previous
studies is the limited number of samples, since the study
was carried out at a single institution. Neither the AmpC β-
lactamase ACC-1, CMY-1-like/MOX, or FOX genes, nor the
carbapenemase OXA-48-like gene, were detected in clinical
isolates of this study. Moreover, since AmpC and carbapenemase
genes are less prevalent than ESBL genes in Korea, we confirmed
and included only ESBL-phenotype isolates in screening. Thus,
there is a possibility that some of the non-ESBL isolates
producing AmpC and/or carbapenemase could not be identified.
Therefore, larger studies are required to confirm our results and
limitations.
In conclusion, the recently developed REBA-EAC assay is
an accurate, rapid, and convenient tool for identifying GNB.
This assay can also discriminate ESBL, AmpC β-lactamase, and
carbapenemase genes and directly detect pathogen species from
PBC samples in only 2 h. Therefore, the REBA-EAC assay can
provide essential information that can accelerate therapeutic
decisions for earlier appropriate antibiotic treatment in the acute
phase of pathogen infection.
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